Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Dec 24, 2025; 16(12): 112443
Published online Dec 24, 2025. doi: 10.5306/wjco.v16.i12.112443
Published online Dec 24, 2025. doi: 10.5306/wjco.v16.i12.112443
Expanding the role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A multicenter study on uncommon peritoneal malignancies
Massimo Framarini, Fabrizio D'Acapito, Daniela Di Pietrantonio, Department of General and Oncologic Surgery, Morgagni-Pierantoni Hospital, AUSL Romagna, Forli 47121, Italy
Piero Vincenzo Lippolis, Department of General Surgery, University Hospital of Pisa, Pisa 56126, Italy
Andrea Di Giorgio, Surgical Unit of Peritoneum and Retroperitoneum, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome 00136, Italy
Antonio Sommariva, Unit of Surgical Oncology of Digestive Tract, Veneto Institute of Oncology IOV - IRCCS, Padua 35128, Italy
Paolo Sammartino, Department of Surgery "Pietro Valdoni", Sapienza University of Rome, Roma 00161, Italy
Co-first authors: Massimo Framarini and Fabrizio D'Acapito.
Author contributions: Framarini M and D'Acapito F contribute equally to this study as co-first authors; Framarini M, Sommariva A and Sammartino P designed the research study; D’Acapito F, Lippolis PV, Di Giorgio A, Sommariva A and Sammartino P collected the data across participating centers; D’Acapito F wrote the initial draft and performed the statistical analysis; Framarini M, D’Acapito F, Di Pietrantonio D, Sammartino P and Sommariva A revised the draft and contributed to the final version; all authors reviewed and approved the final manuscript.
Institutional review board statement: The study protocol was approved by the Hospital Ethics Committee (approval No. 0/23453/F2/RP) on 6 May 2004, in accordance with the Declaration of Helsinki (latest revision) and Good Clinical Practice (GCP) guidelines.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors report no conflicts of interest.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Data sharing statement: Due to current regulations on privacy and the protection of personal data, no additional data can be shared.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fabrizio D'Acapito, PhD, Department of General and Oncologic Surgery, Morgagni-Pierantoni Hospital, AUSL Romagna, Via Carlo Forlanini 34, Forli 47121, Italy. fabrizioda@gmail.com
Received: July 28, 2025
Revised: September 1, 2025
Accepted: November 7, 2025
Published online: December 24, 2025
Processing time: 149 Days and 0.7 Hours
Revised: September 1, 2025
Accepted: November 7, 2025
Published online: December 24, 2025
Processing time: 149 Days and 0.7 Hours
Core Tip
Core Tip: This multicenter retrospective study evaluates the safety and efficacy of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastases (PM) from uncommon primary tumors. Among 60 patients treated across five high-volume centers, long-term survival was observed in selected cases, particularly those with breast or uterine cancer. Tumor origin emerged as the strongest independent predictor of overall survival, whereas timing of PM (synchronous vs metachronous) showed a variable prognostic impact. These findings support CRS + HIPEC as a potentially valuable option in rare indications when patients are carefully selected.